EUVIMEDEUVIMED entdecken
Qualitative StudieOpen Access · CC BY 4.0

Health care providers’ decision-making and early adoption of tenofovir alafenamide for HIV preexposure prophylaxis: An inductive qualitative study

Elisabeth Merchant iD, Patricia Solleveld, Kevin Gibas, Douglas Krakower

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0311591 ↗

Kurz gefasst

Qualitative Studie in der Zeitschrift PLOS ONE, 2024. Verfasst von Elisabeth Merchant und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Tufts Medical Center, Boston, MA, United States of America. Hauptthemen laut MEDLINE: Tenofovir, HIV Infections, Pre-Exposure Prophylaxis, Alanine. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Harvard University Center for AIDS Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Over the past several years, there have been several changes affecting the available options for oral HIV preexposure prophylaxis, including approvals for tenofovir alafenamide with emtricitabine in 2019 and a generic formulation of tenofovir disoproxil fumarate with emtricitabine in 2020.

Methods

In order to better understand providers’ decision-making processes when deciding between these two drugs for pre-exposure prophylaxis, we conducted semi-structured in-depth interviews with resident, fellow and attending physicians in internal medicine and infectious diseases between May 2020 and March 2021. These interviews were analyzed to identify emergent codes, which were utilized in an inductive thematic analysis to identify major themes pertinent to pre-exposure prophylaxis decision-making.

Results

Of 21 participants, 18 expressed a general preference for prescribing tenofovir disoproxil fumarate with emtricitabine, 2 preferred tenofovir alafenamide with emtricitabine and 1 had no specific preference. Providers perceived similar efficacy of the two formulations, and their clinical decisions were influenced primarily by whether HIV pre-exposure prophylaxis users belonged to a population with an indication for each of the two drugs (e.g. gender-related restrictions for tenofovir alafenamide), the medications’ differing side effect profiles, cost and insurance considerations, prior personal and collective experience with each of these medications, and personal preferences. Respondents also noted that both providers and HIV pre-exposure prophylaxis users were influenced by external factors, including institutional prescribing guidance, advertising, and social influences, including from peers and colleagues.

Conclusions

Our findings suggest that unbiased educational campaigns for both prescribers and users of HIV pre-exposure prophylaxis will be important to support evidence-based prescribing practices and cost-effective decisions among oral pre-exposure prophylaxis options.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TenofovirHIV InfectionsPre-Exposure ProphylaxisAlanineAnti-HIV AgentsHumansMaleFemaleAdultHealth PersonnelAdenineMiddle AgedDecision MakingQualitative ResearchEmtricitabine

Substanzen

Tenofovirtenofovir alafenamideAlanineAnti-HIV AgentsAdenineEmtricitabine

Autor:innen und Institutionen

  • Department of Medicine, Tufts Medical Center, Boston, MA, United States of America.
  • Tufts University School of Medicine, Boston, MA, United States of America.
  • T.H. Chan School of Medicine, University of Massachusetts, Worcester, MA, United States of America.
  • Department of Medicine, Rhode Island Hospital, Providence, RI, United States of America.
  • Warren Alpert Brown University School of Medicine, Providence, RI, United States of America.
  • Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, United States of America.

ORCID-Profile: Elisabeth Merchant

Förderung

  • NIAID NIH HHS
  • Harvard University Center for AIDS Research

Zitieren

APA

Merchant, E., Solleveld, P., Gibas, K., & Krakower, D. (2024). Health care providers’ decision-making and early adoption of tenofovir alafenamide for HIV preexposure prophylaxis: An inductive qualitative study. PLOS ONE. https://doi.org/10.1371/journal.pone.0311591

Vancouver

Merchant E, Solleveld P, Gibas K, Krakower D. Health care providers’ decision-making and early adoption of tenofovir alafenamide for HIV preexposure prophylaxis: An inductive qualitative study. PLOS ONE. 2024. doi:10.1371/journal.pone.0311591

BibTeX
@article{Merchant2024,
  author = {Merchant, Elisabeth and Solleveld, Patricia and Gibas, Kevin and Krakower, Douglas},
  title = {Health care providers’ decision-making and early adoption of tenofovir alafenamide for HIV preexposure prophylaxis: An inductive qualitative study},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0311591}
}
Kostenlos starten →